Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

There are no transmission terms in the subcorpus


Seroprevalence
    displaying 1 - 1 records in total 1
    records per page




    Characterisation of Acute Kidney Injury MESHD Acute Kidney Injury HP in Critically Ill Patients with Severe Coronavirus Disease MESHD-2019 (COVID-19)

    Authors: Sebastien RUBIN; Arthur Orieux; Renaud Prevel; Antoine Garric; Marie-Lise Bats; Sandrine Dabernat; Fabrice Camou; Olivier Guisset; Nahema Issa; Gaelle Mourissoux; Antoine Dewitte; Olivier Joannes-boyau; Catherine Fleureau; Hadrien Roze; Cedric Carrie; Laurent Petit; Benjamin Clouzeau; Charline Sazio; Hoang-Nam Bui; Odile Pillet; Claire Rigothier; Frederic Vargas; Christian Combe; Didier Gruson; Alexandre Boyer

    doi:10.1101/2020.05.06.20069872 Date: 2020-05-10 Source: medRxiv

    Background: COVID19-associated acute kidney injury MESHD acute kidney injury HP frequency, severity and characterisation in critically ill patients has not been reported. Methods: Single-center cohort performed from March 3, 2020, to April 14, 2020 in 4 intensive care units in Bordeaux University Hospital, France. All patients with COVID19 and pulmonary severity criteria were included. AKI was defined using KDIGO criteria. A systematic urinary analysis was performed. The incidence, severity, clinical presentation, biological characterisation (transient vs. persistent acute kidney injury MESHD acute kidney injury HP; proteinuria MESHD proteinuria HP, hematuria MESHD hematuria HP and glycosuria MESHD glycosuria HP), and short-term outcomes was evaluated. Results: 71 patients were included, with basal serum SERO creatinine of 69 +/- 21 micromol/L. At admission, AKI was present in 8/71 (11%) patients. Median follow-up was 17 [12-23] days. AKI developed in a total of 57/71 (80%) patients with 35% Stage 1, 35% Stage 2, and 30% Stage 3 acute kidney injury MESHD acute kidney injury HP; 10/57 (18%) required renal replacement therapy. Transient AKI was present in only 4/55 (7%) patients and persistent AKI was observed in 51/55 (93%). Patients with persistent AKI developed a median urine protein/creatinine of 82 [54-140] (mg/mmol) with an albuminuria MESHD albuminuria HP/ proteinuria MESHD proteinuria HP ratio of 0.23 +/- 20 indicating predominant tubulo-interstitial injury. Only 2 (4%) patients had glycosuria MESHD glycosuria HP. At Day 7 onset of after AKI, six (11%) patients remained dependent on renal replacement therapy, nine (16%) had SCr > 200 micromol/L, and four (7%) died. Day 7 and day 14 renal recovery occurred in 28% and 52 % respectively. Conclusion: COVID19 associated AKI is frequent, persistent severe and characterised by an almost exclusive tubulo-interstitial injury without glycosuria MESHD glycosuria HP

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.